# Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations

> **NCT02759614** · PHASE3 · COMPLETED · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 311 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT02759614
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-01
- **Primary completion:** 2018-06-01
- **Final completion:** 2020-03-30
- **Target enrollment:** 311 (ACTUAL)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02759614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02759614, "Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02759614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*